Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Area of Science:

• Virology
• Infectious Diseases
• Antiviral Research

Background:

• Human adenoviruses (HAdV) are common pathogens responsible for respiratory, ocular, and gastrointestinal diseases.
• Severe HAdV infections pose a significant risk to pediatric and immunocompromised populations.
• The lack of specific antiviral therapies for HAdV necessitates the development of novel treatments.

Purpose of the Study:

• To review recent advancements in the development of therapeutic agents against human adenoviruses.
• To focus on antiviral strategies targeting the post-entry stages of the HAdV replicative cycle.

Main Methods:

• Literature review of recent scientific publications and clinical studies.
• Analysis of emerging antiviral compounds and therapeutic approaches.
• Evaluation of targets within the post-entry phase of the HAdV life cycle.

Main Results:

• Identification of several promising therapeutic targets and agents currently under investigation.
• Highlighting strategies that interfere with viral entry, uncoating, or nuclear transport.
• Discussion of the potential efficacy and challenges associated with these novel antiviral approaches.

Conclusions:

• Emerging antiviral therapies targeting post-entry stages show promise for controlling severe HAdV infections.
• Further research and clinical trials are crucial to validate these agents for therapeutic use.
• Development of effective HAdV antivirals is critical given recent outbreaks and the vulnerability of certain populations.